First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis

MS Holleman, H van Tinteren, HJM Groen… - OncoTargets and …, 2019 - Taylor & Francis
Background EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including afatinib, dacomitinib,
erlotinib, gefitinib, and osimertinib have proven efficacy in terms of progression-free survival …
被引用次数：62 相关文章
[PDF] core.ac.uk

[PDF][PDF] First-line tyrosine kinase inhibitors in eGFR mutation-positive non-small-cell lung cancer: a network meta-analysis

MS Holleman, H van Tinteren, HJM Groen… - OncoTargets and …, 2019 - core.ac.uk
Background: EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including afatinib, dacomitinib,
erlotinib, gefitinib, and osimertinib have proven efficacy in terms of progression-free survival …

First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis

MS Holleman, H van Tinteren, H Groen, MJ Al… - Oncotargets and …, 2019 - repub.eur.nl
Background: EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including afatinib, dacomitinib,
erlotinib, gefitinib, and osimertinib have proven efficacy in terms of progression-free survival …

First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis

MS Holleman, H van Tinteren… - OncoTargets and …, 2019 - search.proquest.com
Background: EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including afatinib, dacomitinib,
erlotinib, gefitinib, and osimertinib have proven efficacy in terms of progression-free survival …

First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis

MS Holleman, H van Tinteren, HJM Groen… - Oncotargets and …, 2019 - research.rug.nl
Background: EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including afatinib, dacomitinib,
erlotinib, gefitinib, and osimertinib have proven efficacy in terms of progression-free survival …

First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis

MS Holleman, H van Tinteren… - OncoTargets and …, 2019 - pubmed.ncbi.nlm.nih.gov
Background EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including afatinib, dacomitinib,
erlotinib, gefitinib, and osimertinib have proven efficacy in terms of progression-free survival …
[PDF] scienceopen.com

[PDF][PDF] First-line tyrosine kinase inhibitors in eGFR mutation-positive non-small-cell lung cancer: a network meta-analysis

MS Holleman, H van Tinteren, HJM Groen… - OncoTargets and …, 2019 - scienceopen.com
Background: EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including afatinib, dacomitinib,
erlotinib, gefitinib, and osimertinib have proven efficacy in terms of progression-free survival …

First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis.

MS Holleman, H Tinteren, HJM Groen… - OncoTargets & …, 2019 - search.ebscohost.com
Background: EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including afatinib, dacomitinib,
erlotinib, gefitinib, and osimertinib have proven efficacy in terms of progression-free survival …
[HTML] nih.gov

[HTML][HTML] First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis

MS Holleman, H van Tinteren, HJM Groen… - OncoTargets and …, 2019 - ncbi.nlm.nih.gov
Background EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including afatinib, dacomitinib,
erlotinib, gefitinib, and osimertinib have proven efficacy in terms of progression-free survival …

First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis.

MS Holleman, H van Tinteren, HJ Groen… - Oncotargets and …, 2019 - europepmc.org
Background EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including afatinib, dacomitinib,
erlotinib, gefitinib, and osimertinib have proven efficacy in terms of progression-free survival …